Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany

References

• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993–1004. PubMed PMID: 25176015. DOI:10.1056/NEJMoa1409077
   PubMed Web of Science ®Google Scholar
• Novartis Europharm Ltd. Entresto summary of product characteristics. 2015 [cited 2018 Jan 20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004062/WC500197536.pdf
   Google Scholar
• European Medicines Agency. Entresto. EPAR summary for the public. 2015 [cited 2018 Jan 20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004062/WC500197539.pdf
   Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129–2200. PubMed PMID: 27206819. DOI:10.1093/eurheartj/ehw128
   PubMed Web of Science ®Google Scholar
• Earls S., Zhou S., Mcdonald K. Use of sacubitril/valsartan in a dedicated heart failure centre-real world experience from the first 110 patients. Eur J Heart Fail. 2017;19(Suppl. 1):5–601
   Google Scholar
• Canu A, Maurin V, Dos Santos P, et al. Results of a single center experience on 200 consecutive patients treated with Entresto (sacubitril/valsartan) [abstract]. Presented at the European Society of Cardiology 4th World Congress on Acute Heart Failure, 29 April–2 May 2017, Paris, France. Eur J Heart Fail. 2017;19(Suppl.1):5–601.
   Google Scholar
• Haddad H, Bergeron S, Ignaszewski A, et al. The PARASAIL study. Patient reported outcomes from the Canadian real world experience use of sacubitril/valsartan in patients with heart failure and reduced ejection fraction [abstract]. Presented at the European Society of Cardiology 4th World Congress on Acute Heart Failure, 29 April–2 May 2017, Paris, France. Eur J Heart Fail. 2017;19(Suppl. S1):5–601.
   Google Scholar
• Pharmazeutische zeitung online. New pharmaceuticals. 2016 [cited 2018 Jan 20]. Available from: http://www.pharmazeutische-zeitung.de/index.php?id=61928
   Google Scholar
• Becher H, Kostev K, Schroder-Bernhardi D. Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009 Oct;47(10):617–626. PubMed PMID: 19825325; eng.
   PubMed Web of Science ®Google Scholar
• Hedeker D Generalized linear mixed models. Encyclopedia of statistics in behavioural science. 2005 [cited 2018 Jan 20]. Available from: http://www.wiley.com/legacy/wileychi/eosbs/pdfs/bsa251.pdf
   Google Scholar
• Pinheiro J, Bates D. Mixed-effects models in S and S-PLUS. New York: Springer-Verlag; 2000.
   Google Scholar
• Desai AS, Solomon S, Claggett B, et al. Factors associated with noncompletion during the run-in period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM-HF trial. Circ Heart Fail. 2016 Jun;9(6):6. PubMed PMID: 27296397. DOI:10.1161/CIRCHEARTFAILURE.115.002735
   Web of Science ®Google Scholar
• Zile MR, Claggett BL, Prescott MF, et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2016 Dec 06;68(22):2425–2436. PubMed PMID: 27908347. DOI:10.1016/j.jacc.2016.09.931
   PubMed Web of Science ®Google Scholar
• Wikstrom G, Boman K, Olofsson M, et al. Dosing of heart failure treatments in newly diagnosed unselected patients in sweden: compliance with european society of cardiology guidelines. Eur J Heart Fail. 2016;18(suppl 1):P1496.
   Google Scholar
• Chang C-L, Song X, Willson T, et al. Early assessment of real-world utilization and dosing of sacubitril/valsartan in the US [abstract]. Presented at American Heart Association’s Quality of Care and Outcomes Research 2017 Scientific Sessions, 2–3 April 2017, Arlington, VA, USA. Circulation: Cardiovascular Quality and Outcomes. 2017;10: A220.
   PubMedGoogle Scholar
• Maurin V, Canu A, Bernard A, et al. Early reverse remodelling and improvement of echo parameters after introduction of sacubitril/valsartan in 80 stable and well treated HFrEF patients [abstract]. Presented at the European Society of Cardiology 4th World Congress on Acute Heart Failure, 29 April–2 May 2017, Paris, France. Eur J Heart Fail. 2017;19(Suppl.1):5–601.
   Google Scholar
• Bravo Marques R, Torres Calvo F, Tojero Lopez S, et al. Initial experience using LCZ696 in real life: tolerability and clinical evolution in a short term [abstract]. Presented at the European Society of Cardiology 4th World Congress on Acute Heart Failure, 29 April–2 May 2017, Paris, France. Eur J Heart Fail. 2017;19(Suppl. 1):5–601.
   Google Scholar
• Okumura N, Jhund PS, Gong J, et al. Effects of Sacubitril/Valsartan in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure) according to background therapy. Circ Heart Fail. 2016 Sep;9(9):e003212. PubMed PMID: 27618854; eng. DOI:10.1161/circheartfailure.116.003212
   PubMed Web of Science ®Google Scholar
• Solomon SD, Claggett B, Desai AS, et al. Influence of ejection fraction on outcomes and efficacy of Sacubitril/Valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circ Heart Fail. 2016 Mar;9(3):e002744. PubMed PMID: 26915374; eng. DOI:10.1161/circheartfailure.115.002744
   PubMed Web of Science ®Google Scholar
• Badano LP, Di Lenarda A, Bellotti P, et al. Patients with chronic heart failure encountered in daily clinical practice are different from the “typical” patient enrolled in therapeutic trials. Ital Heart J. 2003 Feb;4(2):84–91. PubMed PMID: 12762270.
   PubMedGoogle Scholar
• Kennedy-Martin T, Curtis S, Faries D, et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015 Nov 03;16:495. PubMed PMID: 26530985; PubMed Central PMCID: PMCPMC4632358. DOI:10.1186/s13063-015-1023-4
   PubMed Web of Science ®Google Scholar
• Jhund PS, Fu M, Bayram E, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015 Oct 7;36(38):2576–2584. PubMed PMID: 26231885; PubMed Central PMCID: PMCPMC4595742. eng. DOI:10.1093/eurheartj/ehv330
   PubMed Web of Science ®Google Scholar
• Bohm M, Young R, Jhund PS, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017 Apr 14;38(15):1132–1143. PubMed PMID: 28158398; eng. DOI:10.1093/eurheartj/ehw570
   PubMed Web of Science ®Google Scholar
• Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017 May;5(5):333–340. PubMed PMID: 28330649. DOI:10.1016/S2213-8587(17)30087-6
   PubMed Web of Science ®Google Scholar